At PILLAR, we pioneered micronutrition into elite performance with a mission to get more athletes to the start line in their best condition.

Today, we're thrilled to unveil our research partnership alongside the Israel - Premier Tech World Tour Cycling team as we expand our offering deeper in the cycling community, but more importantly begin a period of uncharted research into elite endurance and micronutrition supplementation.

Israel - Premier Tech's reputation for innovation mirrors our own commitment to pushing the boundaries on what performance nutrition has long been thought of. Under the guidance of Dr. Dan Plews and Dr. David Bailey, a research study into HRV [Heart Rate Variability] and supplementation intervention on world tour riders will be undertaken across 2024.

With the impact of supplementation on recovery markers such as Heart Rate Variability (HRV) still unknown, this collaboration will unravel the intricate relationship between HRV and supplementation, unlocking insights that will begin a baseline of sports science. This research will also assist our science team to iterate PILLAR product development for the most bespoke outcomes. 


We also welcome health wearable leader, WHOOP, as a key component of this research. Their expertise in data capture and analysis will provide invaluable real time insights.

In essence, this partnership is not just about advancing micronutrition or enhancing performance. It's about rewriting the script, charting new territories, and etching our names in the annals of sports science. Together with Israel - Premier Tech and WHOOP, we're embarking on a journey that will not only redefine excellence but inspire generations to come. This is the dawn of a new era for PILLAR Performance—one marked by relentless innovation and unparalleled dedication to empowering athletes worldwide.


Study Design - Detailed

The initial phase of this investigation (termed as Study 1) will employ a cross-sectional design involving a cohort of 20 professional cyclists from world tour cycling team Israel - Premier Tech (n = 20; 1 team). This study will span an extended duration and comprise multiple instances. Specifically, it will encompass a routine overload training phase lasting 2-3 weeks, alongside cycling sessions of 1-3 weeks, both with and without intervention.


The data collection will involve daily monitoring of baseline Heart Rate Variability (HRV) in terms of rMSSD (root mean square of successive differences), day-to-day HRV fluctuations, as well as assessments of sleep quality and duration. These parameters will be recorded using a WHOOP device. The intervention itself will entail the consumption of a single serving (5g) of PILLAR Performance Triple Magnesium, administered 45 minutes before bedtime each night.


During the phase without intervention, cyclists will receive a placebo drink formulated to match the flavour profile of the Triple Magnesium product, ensuring a consistent taste experience for participants across both intervention and non- intervention periods.